CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 50 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-02 | Hansen Gwenn Chief Scientific Officer | Sale | −1,098 | $11.75 | $13K | 17,151 |
| 2022-05-02 | Wolff Stefani EVP and COO | Sale | −330 | $11.75 | $4K | 632 |
| 2022-05-02 | van Houte Hans Chief Financial Officer | Sale | −697 | $11.75 | $8K | 2,189 |
| 2022-05-02 | Ring Christine General Counsel | Sale | −660 | $11.75 | $8K | 3,403 |
| 2022-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,206 | 18,249 | ||
| 2022-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,206 | 48,102 | ||
| 2022-04-30 | Wolff Stefani EVP and COO | Option exercise | +962 | 962 | ||
| 2022-04-30 | Wolff Stefani EVP and COO | Option exercise · Restricted Stock Units | −962 | 14,430 | ||
| 2022-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 2,886 | ||
| 2022-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 43,291 | ||
| 2022-04-30 | Ring Christine General Counsel | Option exercise | +1,924 | 4,063 | ||
| 2022-04-30 | Ring Christine General Counsel | Option exercise · Restricted Stock Units | −1,924 | 28,861 | ||
| 2022-01-20 | SANDS ARTHUR T President, CEO | Grant or award · Employee Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2022-01-19 | Wolff Stefani EVP and COO | Grant or award · Employee Stock Option (right to buy) | +34,631 | 34,631 | ||
| 2022-01-19 | Wolff Stefani EVP and COO | Grant or award · Restricted Stock Units | +15,392 | 15,392 | ||
| 2022-01-19 | van Houte Hans Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +103,894 | 103,894 | ||
| 2022-01-19 | van Houte Hans Chief Financial Officer | Grant or award · Restricted Stock Units | +46,177 | 46,177 | ||
| 2022-01-19 | Ring Christine General Counsel | Grant or award · Employee Stock Option (right to buy) | +69,262 | 69,262 | ||
| 2022-01-19 | Ring Christine General Counsel | Grant or award · Restricted Stock Units | +30,785 | 30,785 | ||
| 2022-01-19 | Hansen Gwenn Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +115,438 | 115,438 |
Page 29 of 32 · 632 trades